Printer Friendly

Palomar Medical to Debut Next Generation StarLux and New Handpieces at the American Academy of Dermatology Annual Meeting.

BURLINGTON, Mass., Feb. 1 /PRNewswire-FirstCall/ -- Palomar Medical Technologies, Inc. , a leading researcher and developer of light-based systems for cosmetic treatments, announced today that it will unveil the new Palomar StarLux(R) 500 Laser and Pulsed Light System at the 65th Annual Meeting of the American Academy of Dermatology (AAD) in Washington, D.C. from February 3rd to 5th. Palomar will also unveil five new handpieces including the Lux1540-Z(TM) Fractional Laser Handpiece, the LuxDeepIR(TM) Fractional Handpiece, and the LuxW(TM) and LuxYs(TM) Pulsed Light Handpieces. Management will be available at the AAD for investor demonstrations and to discuss Palomar's full line of products in booth #1923 at the Washington Convention Center.

The new Palomar StarLux(R) 500 features 70% more power and increased functionality and speed of treatment as compared to Palomar's successful flagship product the StarLux(R) Laser and Pulsed Light System. Capable of achieving higher peak and average power for greater efficacy with increased contact cooling for added safety and comfort, the StarLux(R) 500 offers customers faster treatment times, more flexibility, improved results, and a faster return on their investment. The StarLux(R) 500 will support the same suite of existing StarLux handpieces, as well as the newest offerings, two of which can only be operated on the StarLux(R) 500 due to its higher power capability.

The new Lux1540-Z(TM) Fractional Laser Handpiece offers fractional soft tissue coagulation and non-ablative skin resurfacing (FDA cleared for soft tissue coagulation. 510(k) submitted for skin resurfacing). Treatment customization is provided by allowing the user to control micro-beam density and focal depth as well as handpiece spot size (up to 15x15 mm). The unique handpiece design allows easy visualization of the treatment area.

The new LuxDeepIR(TM) Fractional Handpiece provides skin tightening through soft tissue coagulation by more safely targeting deeper skin and subcutaneous fat structures. This handpiece features advanced cooling for superior comfort and safety, advanced contact sensors to insure proper cooling, and a longer pulse duration for deeper penetration and higher efficacy. With its fractional light delivery, advanced cooling, and long pulse duration, the LuxDeepIR(TM) is able to penetrate deeper into the dermis and fat layer while preserving the integrity of the epidermis and upper dermis.

The new LuxW(TM) Pulsed Light Handpiece is optimized for treatment of very light pigmented lesions, while the new LuxYs(TM) Pulsed Light Handpiece provides permanent reduction of lighter, finer hair.

Chief Executive Officer Joseph P. Caruso commented, "Due to the remarkable success achieved by the original StarLux(R) System, many of our competitors are struggling to launch "me too" systems. With Palomar's launch of the StarLux(R) 500, however, we again leap frog over our competitors to offer a significantly advanced system with the further benefit that it is built on the already proven and successful StarLux platform. The StarLux(R) 500 will again raise the bar in our industry for performance, capability, reliability, and safety. In addition, the launch of four new handpieces, with more to come, demonstrates our commitment to providing the most reliable, cost effective, expandable aesthetic system available."

To reserve a time to meet with Palomar management and/or receive product demonstrations, please contact Palomar's Investor Relations' department at 781-993-2411 or

About Palomar Medical Technologies Inc: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. On December 8, 2006, Palomar became the first company to receive a 510(k) over- the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is uniquely focused on developing proprietary light- based technology for introduction to the mass markets. Palomar has an agreement with The Gillette Company to develop and potentially commercialize a patented home-use, light-based hair removal device for women. Palomar also has an agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.

For more information on Palomar and its products, visit Palomar's website at To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations' section of the website.

With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including but not limited to statements relating to new markets, future royalty amounts due from third parties, development and introduction of new products, and financial and operating projections (including future tax benefit from the Company's NOLs and future effective tax rates). These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2005 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
 Contact: Kayla Castle
 Investor Relations Manager
 Palomar Medical Technologies Inc

CONTACT: Kayla Castle, Investor Relations Manager of Palomar Medical Technologies Inc., +1-781-993-2411, or

Web site:

Company News On-Call:
COPYRIGHT 2007 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 1, 2007
Previous Article:David Zabetakis Joins CURRENT to Lead Business Development.
Next Article:VTEX Announces Phase One Completion Progress Report on Investment in UK North Yorkshire Natural Gas and Electrical Power Generation Project.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters